To analyse the impact of repeating a prostate-specific antigen (PSA) level assessment on prostate biopsy decision in a cohort of men undergoing prostate biopsy.
Introduction
Prostate cancer is the second most commonly diagnosed malignancy in men, with an estimated 1.1 million diagnoses worldwide in 2012 [1] . Prostate cancer diagnosis is driven most of the time by a persistent elevation in serum PSA levels, which triggers a prostate biopsy [2] . However, PSA is far from ideal as a tumour marker, as its accuracy is low, and leads to many unnecessary prostate biopsies [3] . PSA variability has been extensively investigated and the most recent European Association of Urology (EAU) guidelines recommend a second PSA test after a few weeks, using the same assay under standardised conditions in the same laboratory, before any prostate biopsy [4] . Particularly, Eastham et al. [5] reported that nearly half of men who had one abnormal PSA level subsequently had normal levels.
Singh et al. [6] reported that a second normal PSA level result avoids a considerable number of unnecessary prostate biopsies, with an acceptable risk of missing low-grade and a very low risk of missing high-grade prostate cancer. However, only a few studies have evaluated the clinical impact of a second PSA level decrease or increase in terms of prostate cancer diagnosis. Recently, Nordstr€ om et al. [7] assessed the value of a second PSA test taken before biopsy in a group of patients with PSA levels of 3-10 ng/mL. According to their results, a decrease in PSA level is related to a lower risk of high-grade prostate cancer, whilst a rise is not related to a higher risk of prostate cancer. With this knowledge in mind, the aim of our present study was to evaluate cancer detection rates in relation to PSA variations in a cohort of Italian men undergoing prostate biopsy.
Patients and Methods

Study Population and Design
From January 2015 to January 2016, patients referred to our prostate clinic with a PSA level ≥4 ng/mL were scheduled for TRUS-guided prostate biopsy 4 weeks after the initial visit. All patients signed a dedicated informed consent, all the procedures were approved by the Local Ethics Committee, and the study was conducted in accordance with the principles of the Declaration of Helsinki. We excluded from the study patients who had a history of prostate cancer or prostate surgery, positive DRE, patients on 5a-reductase inhibitor treatment, and patients with previous negative biopsies.
The prostate biopsies were taken as outpatient procedures. All patients underwent a 12-core TRUS-guided biopsy using Falcon ultrasound equipment (B-K Medical, Milan, Italy), equipped with a 5-10 MHz bi-convex probe (8808 probe B-K Medical). We used a 16-G biopsy needle (Magnum 1000, BARD, Rome, Italy) and a dedicated spring-loaded biopsy gun (MG1522, BARD). Antibiotic prophylaxis (peri-procedure i.v. amikacin 1 000 mg) and peri-prostatic anaesthetic block were performed according to our departmental protocol [8] . Before the biopsy procedure, patients underwent a detailed physical examination including DRE.
High-grade disease was defined as Grade group ≥3 [9] . A single pathologist, who was blinded to the clinical data except for age, was involved in the study.
Patients with negative biopsies were followed for 1 year with PSA testing and DRE every 6 months, according to our department's protocol.
PSA Assessment
PSA levels were assessed twice: the day of enrolment (PSA 1 ) and 4 weeks later on the day before biopsy (PSA 2 ). Patients with a PSA level >20 or <4 ng/mL, patients with any sexual activity in the 2 days before PSA assessment, and patients with any antibiotic treatment in the 4 weeks before PSA testing, were excluded from the analysis. All the samples were analysed in the same laboratory and with the same test. The IMMULITE â 2000 (Siemens, Munich, Germany) chemoluminescent enzyme immunoassay method, which is a solid phase, sequential chemiluminescent immunometric assay, was used to determine PSA levels (ng/mL).
Statistical Analysis
Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS â ) version 24.0 software (SPSS Inc., IBM Corp., Armonk, NY, USA). Sample size calculation was calculated with the method described by Kelsey et al. [10] , using an a value of 5% and a b value of 20%. The expected incidence of a >20% PSA level reduction was 15%, as reported by Nordstr€ om et al. [7] , and in this group of patients we supposed a 50% reduction in the risk of prostate cancer compared to the rest of the population. The minimum sample size was 322. Allowing for a 10% risk of discontinuation, we planned to enrol 350 patients. Evaluation of data distribution, using the Kolmogorov-Smirnov test, showed a non-normal distribution of all the variables included in the study. Differences between groups of patients in medians for quantitative variables and differences in distributions for categorical variables were tested with the Mann-Whitney test and chi-squared test, respectively. PSA variations were calculated as (PSA 2 -PSA 1 )/PSA 1 and defined as: stable PSA 2 within 10% variation (e.g. PSA 1 = 7.0 ng/mL and PSA 2 = 7.3 ng/mL), stable PSA 2 within 20% variation (e.g. PSA 1 = 7.0 ng/mL and PSA 2 = 8.0 ng/mL), PSA 2 decreased by ≥10% (e.g. PSA 1 = 7.0 ng/mL and PSA 2 = 6.7 ng/mL), PSA 2 decreased by ≥20% (e.g. PSA 1 = 7.0 ng/mL and PSA 2 = 5.0 ng/mL), PSA 2 increased by ≥10% (e.g. PSA 1 = 7.0 ng/mL and PSA 2 = 7.8 ng/mL), PSA 2 increased by ≥20% (e.g. PSA 1 = 7.0 ng/mL and PSA 2 = 10.0 ng/mL), and PSA 2 <4 ng/mL [7] . PSA variations were assessed as predictors of prostate cancer and high-grade disease respectively, with binary and multinomial age-adjusted regression analysis. A subgroup analysis was performed for patients with a PSA level of ≤10 ng/mL. Data are presented as medians (interquartile ranges [IQRs] ). Odds ratios (ORs) and 95% CIs were calculated for the parameters in each model.
Results
The overall characteristics of the cohort are listed in Table 1 . Prostate cancer was diagnosed in 153/331 (46%) of the patients. These patients were older, with smaller prostates, higher family history rates, and lower PSA levels ( Table 2) . High-grade prostate cancer was diagnosed in 80/153 (52%) of the patients and these patients were older and with higher PSA levels ( Table 2 ).
Stable PSA 2
In patients with a stable PSA within a 10% range, 59/110 (54%) had prostate cancer and of them 32/59 (54%) had 84 © 2018 The Authors BJU International © 2018 BJU International high-grade disease. When adjusting for age, this group of patients had a higher risk of prostate cancer (OR 1.68, P = 0.032) and high-grade disease (OR 1.83, P = 0.04) when compared to the rest of the study population. However, the risk of low-grade prostate cancer was comparable. Also, in patients with a stable PSA within a 20% range, 100/196 (51%) had prostate cancer and of them 55/100 (55%) had highgrade disease. These patients were at increased risk of prostate cancer (OR 1.97, P = 0.02) and high-grade disease (OR 2.56, P = 0.01). However, the risk of low-grade prostate cancer was comparable (Table 3) . Moreover, these results were even more significant when analysing patients with a PSA level of ≤10 ng/mL (Table 4 ).
Decreased PSA 2
In patients with a decrease in PSA levels of ≥10% and ≥20%, 48/128 (38%) and 24/76 (32%) had prostate cancer, respectively. The high-grade prostate cancer rates were respectively, 10/48 (21%) and five of 24 (21%). Prostate cancer (OR from 0.48 to 0.37) and high-grade disease risk (OR from 0.28 to 0.13) progressively decreased as PSA levels decreased ( Table 3 ). The risk of low-grade prostate cancer, independently of the PSA level decrease threshold, was comparable to the rest of the population (Table 3 ). All these results were more significant when analysing the population with a PSA level range of 4-10 ng/mL (Table 4 ).
Increased PSA 2
In patients with an increase in PSA levels of ≥10% and ≥20%, 46/93 (49%) and 29/59 (49%) had prostate cancer, respectively. The high-grade prostate cancer rates were respectively, 30/46 (65%) and 20/29 (69%). Patients with an increase in PSA levels did not have an increased risk of prostate cancer or low-grade prostate cancer when compared to the rest of the cohort (Table 3 , Fig. 1 ). However, patients with an increase in PSA levels had an increased risk of highgrade prostate cancer (Table 3) .
PSA 2 <4 ng/mL
Overall, 35/331 (11%) patients had a second PSA level of <4 ng/mL and of them 10/35 (29%) had prostate cancer, and one of the 10 had high-grade disease. When adjusting for age, this group of patients had a lower prostate cancer risk (OR 0.33, P = 0.01) and high-grade disease risk (OR 0.06, P = 0.01) when compared to the rest of the study population. However, the risk of low-grade prostate cancer was comparable. These results were even more significant when considering patients with PSA levels between 2 and 10 ng/mL.
Discussion
The present study shows the clinical impact of a second PSA test on cancer detection rates, before prostate biopsy, in men at increased risk of prostate cancer. More specifically, we confirm that the risk of prostate cancer and high-grade disease is reduced when the second PSA level decreases. In our present series, 153/331 (46%) of the patients with a PSA level ≥4 ng/mL had prostate cancer and of them 80/153 (52%) had high-grade disease, defined as Grade group ≥3. Moreover, patients with prostate cancer were older, with smaller prostates, and with higher PSA levels when compared to patients without prostate cancer. These results are consistent with the literature and confirm the internal validity of our study [11, 12] .
According to the 2017 EAU guidelines, limited PSA elevation alone should not prompt immediate biopsy [4] . Nevertheless, there are no indications on the clinical implications of a decrease, increase or stable second PSA level. Moreover, most of the available evidence is retrospective, concentrates on fluctuations of PSA over years, and include patients with previous negative biopsies [13, 14] . In 1997, Roehrborn et al. [15] evaluated PSA variations within 90 days and found that only 6% of the patients had the same PSA level on both occasions. They concluded that clinicians should not rely on a single PSA measurement; however, they did not analyse the oncological outcomes of PSA fluctuations. To our knowledge only Nordstr€ om et al. [7] have addressed this issue. They evaluated biopsy outcomes of 1 686 men from the Stockholm 3 study (STHLM3) with a PSA level between 3 and 10 ng/ mL, and two PSA tests were undertaken within 8 weeks and before prostate biopsy. According to their analysis, a stable second PSA level increased the risk of high-grade prostate cancer; whilst a decrease/increase in the second PSA level decreased the risk of high-grade prostate cancer. Moreover, they concluded that omitting prostate biopsy for men with PSA values decreasing to levels of ≤3 ng/mL would save 17% of biopsy procedures, whilst missing 5% of high-grade cancers. Our present study confirmed and validated the Nordstr€ om et al. [7] results in a different population, with different biopsy indications (PSA level ≥4 ng/mL), higher cancer risk (46% vs 36%), and a different histological classification [9] . More specifically, in our experience, omitting prostate biopsy in patients with a decrease in PSA levels of ≥20% would save 23% of biopsy procedures, whilst missing 2% of high-grade cancers (Grade group ≥3). Moreover, patients with an increase in PSA levels of ≥10% are at an increased risk of high-grade disease and should therefore undergo prostate biopsy as planned. Although, the latter result is probably related to our case distribution and to the low-/high-grade cancer rate observed in the different PSA groups (Fig. 1) . Moreover, we included in our present analysis patients with a PSA level >10 ng/mL, which were excluded by the previous analysis and we used the same biopsy template (12 cores) in the entire cohort. According to our present results, PSA level changes should be considered when evaluating patients at risk of prostate cancer and these findings may also have an impact on the available prostate cancer risk calculators [16] [17] [18] [19] , which include a single PSA value and do not consider PSA variations. Prostate cancer risk was as high as 53% in patients with a stable PSA, whilst patients with a decrease in PSA levels of ≥20% had a 33% risk of prostate cancer. Nonetheless, most of the cancers diagnosed in the stable PSA group were high-grade cancers (>50%), whilst only 15% of the patients with a decrease in the second PSA level had high-grade disease. Adding PSA variations to the available risk calculators could improve predictive accuracy of the models and such a study is ongoing in our department.
Although our findings are consistent with other experiences, the molecular pathways behind our results are mostly unknown and PSA levels may change as a consequence of several physiological or inflammatory conditions [20] . One possible explanation may be that those patients with stable elevated PSA levels do not hide any other condition that may affect their PSA levels in the short term. Many studies evaluating PSA velocity have shown that patients with prostate cancer typically show gradual rising in PSA levels, which is consistent with our hypothesis [14] .
We have to acknowledge some limitations to our present study. The study is a single centre analysis in a precise geographical area and therefore our results clearly depend on the enrolled population and cannot be extended to all patients at risk of prostate cancer undergoing prostate biopsies. Moreover, prostate cancer diagnosis was made by random prostate biopsies, therefore some tumours could have been missed or under-graded; however, to minimise this potential bias patients with negative biopsies were followed for at least a year with PSA testing and DRE every 6 months and no further cancers were detected. The lack of multiparametric MRI data may represent another limitation in the present study; however, according to the latest EAU guidelines there is still not enough data to recommend MRI in biopsy na€ ıve patients. A prospective study including MRI data is ongoing in our department and results will soon be available. Notwithstanding all these limitations, this is the first available study using the new Grade Group classification in an Italian population, where health screening policies and prevalence of cancer may differ from those observed in other countries.
In a cohort of Italian men undergoing 12-core prostate biopsy, a reduction of ≥20% in PSA levels significantly reduces the risk of high-grade prostate cancer. Although further multicentre studies should be conducted to confirm and validate our present results, we believe that PSA variability could represent a new risk factor for prostate cancer diagnosis and particularly for high-grade disease, with a possible implication on the validity of the current available risk calculators and nomograms.
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